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IMAGING PARKINSON’S DISEASE:







Parkinson’s disease (PD) is a progressive neuro-
degenerative disorder with common symptoms 
including rigidity, tremors, and bradykinesia. 
While current medication can alleviate symp-
toms, no treatment exists to stop or slow neuro-
nal cell death and disease progression. There is 
an unmet need for a biomarker associated with 
progression that could aide in development of 
treatments by monitoring disease progression. 
Since Magnetic Resonance Imaging (MRI) al-
lows for the measure of gray matter (GM) density 
in the human brain noninvasively, this study was 
designed to investigate the association between 
brain atrophy, measured by MRI, and motor dys-
function in PD subjects, as a biomarker. 
MRI and voxel-based morphometry methods were 
used to investigate GM atrophy and the association 
with motor impairment in 43 PD and 59 control 
subjects. T1-weighted whole-brain MRI images 
were acquired in collaborative studies in Germany 
and at Indiana University on 3T MRI scanners. 
Group differences in GM density between PD and 
control subjects were examined voxel by voxel 
with SPM12 using cluster-corrected two-sample 
t-tests. Among PD subjects, associations of GM 
density with motor dysfunction (measured by UP-
DRS-III) were analyzed by multiple regression. 
Compared to controls, PD subjects show signif-
icant GM atrophy in the supplementary motor 
cortex (p < 0.005). This is a critical brain region, 
linking cognition to action. Among PD subjects, 
there is a signifi cant association (p < 0.001) 
of GM atrophy with motor dysfunction (high 
UPDRS-III) bilaterally in the superior parietal 
lobules of the motor cortex. These fi ndings agree 
with the hypothesis that motor dysfunction is 
associated with GM atrophy in the motor cortex, 
and that imaging GM density by MRI is a good 
display of neurodegenerative progression in PD. 
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Parkinson’s disease (PD) is one of the most common 
neurodegenerative diseases with symptoms includ-
ing tremor, bradykinesia (slowness of movement), 
rigidity, and impaired posture control (Miller & 
O’Callaghan, 2015). PD is characterized by the loss 
of dopaminergic neurons in the substantia nigra, 
but neurodegeneration is more widespread. While 
medication can alleviate certain PD symptoms, no 
treatment exists to slow the disease progression. 
Therefore, there is a great need for the development 
of a treatment method that can help slow down or 
reverse the neurodegeneration incurring among 
PD patients. Typically, a PD diagnosis is based on 
observed symptoms in the clinic, such as using 
the Unifi ed Parkinson’s disease Rating Scale 
(UPDRS-III) which measures motor impairment. 
Yet, there is no objective biomarker that allows 
diagnosis or monitoring of disease progression for 
PD patients.
In recent years, medical imaging techniques have 
made advances as a potential solution to diagnose 
and monitor treatment strategies. In particular, 
Magnetic Resonance Imaging (MRI), which provides 
multiple contrasts and functional information, may 
provide more information regarding the pathological 
process of neurodegenerative diseases like PD.
Voxel-based morphometry (VBM) enables a whole-
brain voxel-wise comparison of gray matter (GM) 
and white matter (WM) using MRI images. A voxel 
refers to a small volume of space, often used in 
imaging or three-dimensional modeling. VBM can 
help characterize and identify subtle changes in brain 
structures in a wide variety of neurologic and psy-
chiatric dysfunction diseases. Since VBM measures 
the density of GM in the brain, that is, is a measure 
of neuronal density, it should be a suitable tool to 
measure neurodegeneration and its progression in 
PD. All subcortical areas commonly associated with 
PD, including the caudate nucleus, the putamen, the 
globus pallidus, the subthalamic nucleus, and the 
substantia nigra, have been found to show signifi cant 
atrophy using VBM (Lin et al., 2013). However, these 
changes have not been sensitive enough to serve as 
biomarker of progression for PD. Moreover, it has 
been shown that a high concentration of iron leads to 
incorrect classifi cation of tissues in these subcortical 
structures (Lorio et al., 2016).
Recently, literature has also shown GM atrophy 
present in cortical brain areas that are not typically 
associated with PD, including the frontal lobe, 
intraparietal sulcus, the temporal lobe, parietal 
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stimulated by the environment. Figure 1 maps 
these two loops. Being able to noninvasively study 
progressive changes in GM density associated to 
these motor loops is therefore of particular interest 
in monitoring PD patients.
AIMS/PURPOSE
There is an unmet need for an objective biomarker 
associated with progression of disease—in particular 
with worsening motor function. If sensitive enough, 
such a biomarker could even allow intervention at 
the onset of disease before severe symptoms appear. 
It could also help with early diagnosis of atypical 
parkinsonism, which requires different treatment, or 
help to monitor disease modifying therapy (Miller & 
O’Callaghan, 2015).
 
Therefore, the purpose of this present study was to 
evaluate the relationship between GM atrophy in 
PD patients compared to control subjects, and how 
it relates to motor dysfunction. VBM was used to: 
(1) assess the difference in GM density between 
PD patients and control subjects and (2) investigate 
differences in GM density with decreased motor 
function across PD patients. 
METHODS
Voxel-Based Morphometry (VBM)
MRI is used to study structural changes in the brain. 
VBM is a neuroimaging analysis technique that 
allows the investigation of structural changes in the 
brain using statistical parameter mapping. In this 
study, VBM was used to investigate changes in GM 
density in PD patients and associations with motor 
impairment in PD. 
Subjects
A total of 43 PD patients and 59 controls were used 
in this analysis. All patients and controls in the study 
were male. MRI data was obtained from two collab-
orative PD studies: 24 PD patients and 43 controls 
were recruited at Ruhr University in Bochum, Ger-
many. Nineteen PD patients and sixteen controls were 
lobe, and occipital lobes (Burton, McKeith, Burn, 
Williams, & O’Brien, 2004; Lee et al., 2014; 
Weintraub et al., 2012; Melzer et al., 2012; Sterling 
et al., 2017). However, results were inconsistent. 
The discrepancies across studies may be due to 
inhomogeneous subjects, such as the heterogeneity 
amongst different subtypes of parkinsonism, 
displaying different types of symptoms. 
 
Since PD is classified as a movement disorder, most 
damage has been found in motor loops of the central 
nervous system (Draganski & Bhatia, 2010). These 
motor loops connect the subcortical brain regions 
commonly associated with PD to cortical brain 
regions executing movement and cognition. First, 
the basal ganglia-thalamocortical loop interconnects 
the structures of the basal ganglia (including the 
substantia nigra), the prefrontal cortex, and the sup-
plementary motor cortex (Ash et al., 2011). This loop 
and associated brain regions are very important for 
motor behavior. An additional pathway to consider 
is the cerebello-thalamocortical loop connecting the 
prefrontal cortex, the thalamus, and the cerebellum. 
This pathway plays a key role to regulate actions 
Figure 1. Summary of motor loops, connecting cortical 
and subcortical brain regions.
Table 1. PD and control subject demographics.
Study Scanner Subjects Median Age (Years) Median UPDRS-III
Ruhr University,
Bochum, Germany
3T Philips Achieva PD n = 24 62 30
Controls n = 43 59 1
Indiana University,
Indianapolis, Indiana
3T Siemens Trio PD n = 19 63 31





The SPM output is given as spatial x, y, z coordi-
nates of voxels, each associated with a proportional 
density of GM within the voxel. This method allows 
a voxel-by-voxel statistical comparison across a large 
sample of MR images. SPM12 also allows the display 
of neuromorphometric regions in which the user can 
identify a coordinate-based brain region related to 
significant findings as part of the statistical analysis. 
Statistical Analysis
An SPM12 significance map is created to identify 
and highlight areas of statistical significance depend-
ing on the user-defined threshold. To analyze GM 
differences between 43 PD patients and 59 normal 
control subjects, a two-sample t-test was performed 
with age and intracranial volume as covariates. For 
the group difference, the significance was set to  
p < 0.005. To account for multiple comparisons 
across the many voxels, a cluster size threshold of  
> 200 voxels was set.
 
To investigate an association between GM atrophy 
and motor dysfunction, a multiple regression analysis 
was completed across the 43 PD subjects and their 
UPDRS-III scores, correcting for age and intracranial 
studied at Indiana University School of Medicine 
(IUSM) in Indianapolis, Indiana. Demographics of 
subjects are summarized in Table 1.
Motor Dysfunction Assessment
To assess individual motor function, all subjects 
were scored by certified neurologists using the motor 
part of the Unified Parkinson Disease Rating Scale 
(UPDRS-III), which assesses the ability to perform 
various motor tasks. A higher UPDRS-III score 
indicates increased motor impairment. It should be 
noted that PD patients from Bochum were taking 
medication, which may influence their UPDRS-III 
scores, whereas patients in the study at IUSM were 
either medication-naïve or withheld medication for 
at least 12 hours prior to their UPDRS-III evaluation 
and MRI scans.
MRI
High resolution T1-weighted magnetic resonance 
images (MPRAGE) were acquired on 3.0 Tesla 
whole-body MRI systems for all subject groups. 
T1-weighted MRI’s provide tissue contrast,  
which is useful when distinguishing GM, WM,  
and cerebrospinal fluid (CSF). Data was acquired  
on a Philips Achieva MRI system at Bochum and on 
a Siemens TIM Trio system at IUSM. Imaging pa-
rameters included TR/TE = 8.3/2.7 milliseconds and 
an acquisition matrix of 240x240x240, yielding a 
resolution of 1x1x1 mm3. Each complete whole-brain 
MRI scan contained 220 slices.
Data Analysis
To determine GM density, Statistical Parameter 
Mapping (SPM12) Functional MRI software was 
used in conjunction with MATLAB to determine 
GM density. The flowchart in Figure 2 outlines  
the process. The T1-weighted images acquired in 
Bochum and Indianapolis were first coregistered  
into the same imaging plane, which places all  
images in the same orientation. Next, images  
were segmented into GM, WM, and CSF on a 
voxel-by-voxel basis, analyzing image contrast. As 
a result, a probability map is created proportional 
to the density of GM, WM, and CSF in each voxel. 
Images are then normalized to a standard brain atlas, 
retaining individual GM, WM, and CSF probabili-
ties. Finally, an 8mm full-width-at-half-maximum 
(FWHM) Gaussian kernel filter was applied. This 
spatial smoothing is set to remove noise and random 
signal, increasing the validity of SPM12. Figure 3 
exemplifies the transition of the original T1-weighted 
image before and after processing.  
Figure 3. Left: Original sagittal T1-weighted MRI;  
Middle: T1-weighted MR image after segmentation, nor-
malization, and smoothing; Right: T1 template image.
Figure 2. SPM12 processing sequence.
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Additionally, our findings agreed with the hypoth-
esis that motor dysfunction is associated with GM 
atrophy in the motor cortex in PD patients. Our 
results are in line with a previous study that has seen 
significant GM atrophy in the motor cortex being as-
sociated with disease severity (Wu & Hallett, 2005). 
Atrophy in these brain regions could also explain 
that, compared to normal subjects, PD patients have 
been shown to have less neural activity in the parietal 
lobules of the motor cortex (Zhang et al., 2015).
 
As previously discussed, the supplementary motor 
cortex is a part of the basal ganglia-thalamocortical 
loop. Activation of this loop is important for volun-
tary movement. With a loss of neuronal function in 
the supplementary motor cortex due to GM atrophy 
(i.e., loss of neurons), these findings indicate that GM 
atrophy could be related to voluntary motor control 
in PD. Therefore, these findings agree with the hy-
pothesis that severity of PD motor symptoms can be 
associated with GM atrophy.
Limitations of our Study: Experimental Design
In order to increase the sample size for statistical 
comparison, we pooled two studies, which bears its 
own limitations. For example, the 16 healthy controls 
from the IUSM study had a relatively high median 
UPDRS-III score of 3, as was noted in Table 1. Ide-
ally, a healthy control should have a very low rating 
(less than 2) on a UPDRS-III scale, which might 
slightly increase with age. The difference could be 
due to a scoring inconsistency between the raters of 
the two studies which could alter the group differ-
ence analysis. In future studies, the same rater should 
be scoring all subjects to avoid such inconsistencies. 
Furthermore, the Bochum PD patients were not with-
holding medication at the time of the study, as did 
the IUSM PD patients. This may have an effect on 
their UPDRS-III scores, which could have an impact 
on the regression with motor dysfunction findings. 
Additionally, the Bochum control subjects were not 
matched in socioeconomic background and education 
due to recruitment via newspaper advertisements. 
Alcohol and substance abuse may additionally have 
been a confounding variable.
 
Finally, the sample size in this study was relatively 
limited. Increasing the sample size could improve the 
accuracy and validity of the results. 
Limitations of Voxel-Based Morphometry
With respect to the use of VBM, many studies show 
variable results. Despite the potential of using VBM 
as a biomarker of progression of neurodegeneration, 
volume. A significance threshold of p < 0.001 with a 
cluster size > 200 voxels was used. 
RESULTS
Group Differences
Compared to normal controls, a significant  
(p < 0.005, cluster size > 200) GM atrophy was found 
in PD patients in the left supplementary motor cortex 
of the frontal lobe. Figure 4 highlights the GM differ-
ences on a T1-weighted overlay.
 
Regression with Motor Dysfunction
Among PD subjects there is a significant (p < 0.001, 
cluster size > 200) association of GM atrophy with 
increased UPDRS-III scores in the right and left su-
perior parietal lobules of the motor cortex as shown 
in Figure 5.
DISCUSSION
Our analysis revealed differences among PD and 
control subjects in the supplementary motor cortex. 
The supplementary motor cortex is a critical brain 
region that works to link cognition to action (Nachev, 
Kennard, & Husain, 2008). These findings are in line 
with previous literature showing GM atrophy in the 
frontal lobe and supplementary motor cortex across 
PD patients (González-Redondo et al., 2014).
 
Figure 4. Group differences: Compared to controls, 
significant GM atrophy is seen in the left supplementary 
motor cortex of PD patients (p-value < 0.005, cluster 
size > 200).
Figure 5. Regression with motor function: Within PD 
subjects lower motor performance (higher UPDRS-III 
score) correlated with lower GM density in the left and 
right superior parietal lobes of the motor cortex (p-val-
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there are numerous drawbacks that may impede its 
usefulness in the clinic at this time. For example, GM 
atrophy in PD patients is very small, less than a few 
percent difference at onset of disease (Ash et al., 2011). 
More progressed disease may see more advanced 
degeneration. For this reason, it is essential to improve 
accuracy and reduce sources of error in volumetry 
techniques to produce reliable conclusions. 
 
Moreover, the coherence across VBM studies is lack-
ing, especially in neurodegenerative diseases like PD. 
Some studies have shown a wide range of GM atrophy 
across several brain regions, while others find no sig-
nificant differences. The large range in findings is not 
unexpected, as long as PD patients are not stratified for 
their diverse symptoms (for example, with or without 
dementia, etc.) and potential for atypical PD. These dif-
ferent clinical symptoms rely on many different brain 
regions associated with motor control and cognitive 
processing of voluntary movement and may thus affect 
these brain regions differently in these subpopulations.
 
If obstacles such as these are overcome, VBM may 
prove to become a successful biomarker in PD and 
other neurodegenerative diseases, helping in the  
development of treatment options by being able to 
objectively monitor progression of the disease, irre-
spective of medication status.
CONCLUSION
Overall, noninvasive MRI can be a useful tool to 
identify GM atrophy in PD patients and changes in 
GM density that are associated with specific symp-
toms, such as motor impairment, to serve as marker 
of disease progression. Congruence among several 
studies will validate results observed in this study 
as well as previous literature. Our study is one step 
toward this validation.
Figure 6. 2017 Dydak lab group in the new Purdue MRI 
Facility. Photo courtesy of Ulrike Dydak.
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